CIK对卵巢癌及宫颈癌患者免疫功能的影响  

Effects of cytokine-induced killer cells on immune function in treatment of patients with ovarian cancer and cervical cancer

作　　者：于腾阁 赵晶 李晓利 刘雅莉[2] 刘广芝 YU Teng-ge;ZHAO Jing;LI Xiao-li;LIU Ya-li;LIU Guang-zhi(Department of Obstetrics and Gynecology,People’s Hospital of Zhengzhou University,Henan Provincial People’s Hospital,Zhengzhou 450003,China)

机构地区：[1]郑州大学人民医院,河南省人民医院妇产科,郑州450003 [2]河南省医学情报研究所,郑州450046

出　　处：《医药论坛杂志》2020年第5期8-11,共4页Journal of Medical Forum

基　　金：2018年河南省科技基础条件建设专项:河南省循证医学资源库平台建设(豫财科【2018】6号)。

摘　　要：目的研究CIK对卵巢癌及宫颈癌患者免疫功能的影响。方法回顾性分析2012年1月至2014年12月河南省人民医院收治的复发性卵巢癌患者及经手术或放化疗的宫颈癌患者经辅助CIK治疗各15例。采用自身前后对照的方法,比较患者CIK治疗前后外周血T细胞亚群分布和细胞因子分泌情况。结果T细胞亚群中,卵巢癌患者治疗后总T淋巴细胞、辅助性T细胞、免疫功能及NK细胞分别为(74.27±12.49)%、(36.94±8.89)%、(1.00±0.42)、(25.94±9.25)%较治疗前(68.46±13.78)%、(32.53±9.75)%、(0.79±0.39)、(16.77±7.80)%均显著升高,治疗后抑制性T细胞和调节性T细胞分别为(37.40±5.85)%、(4.56±2.03)%较治疗前(44.89±11.58)%、(5.65±1.43)%均显著下降(P<0.05)。宫颈癌患者治疗后总T淋巴细胞、辅助性T细胞、免疫功能及NK细胞分别为(53.69±11.37)%、(28.77±5.69)%、(1.02±0.39)、(21.75±6.89)%较治疗前(42.63±8.20)%、(25.03±5.85)%、(0.70±0.36)、(17.62±7.72)%均显著升高,治疗后抑制性T细胞和调节性T细胞分别为(30.00±8.42)%、(7.45±3.48)%较治疗前(40.42±11.27)%、(10.44±3.70)%均显著下降(P<0.05)。细胞因子中,卵巢癌患者治疗后IFN-γ为(8.43±1.38)pg/mL较治疗前(6.84±1.48)pg/mL显著升高,IL-10、IL-4和IL-2治疗后分别为(3.50±0.76)pg/mL、(3.24±0.13)pg/mL、(3.94±1.28)pg/mL较治疗前(5.23±1.30)pg/mL、(4.65±1.35)pg/mL、(6.63±2.96)pg/mL显著下降(P<0.05),TNF-α和IL-6治疗前后无显著性差异(P>0.05)。宫颈癌患者IFN-γ和TNF-α治疗后为(38.97±30.80)pg/mL、(8.25±2.28)pg/mL较治疗前(9.14±3.20)pg/mL、(4.33±3.15)pg/mL均显著升高(P<0.05),IL-10、IL-6、IL-4和IL-2治疗前后无显著性差异(P>0.05)。结论CIK能够改善卵巢癌及宫颈癌患者T细胞亚群分布和细胞因子的分泌,提高患者免疫功能。Objective To evaluate the effects of cytokine-induced killer cells(CIK)on immune function in the treatment of patients with ovarian cancer and cervical cancer.Methods Fifteen ovarian patients recurred after surgery and chemotherapy and fifteen cervical patients received surgery or chemoradiotherapy were treated with CIK in the Henan Provincial People’s Hospital from Jan.2012 to Dec.2014,who were enrolled into this retrospective analysis.The T cell subsets distribution and cytokines secretion in peripheral blood were compared before and after CIK treatment.Results In T cell subsets of ovarian cancer patients,CD3^+,CD3^+CD4^+,CD4^+/CD8^+ and NK cells after treatment(74.27±12.49)%,(36.94±8.89)%,(1.00±0.42),(25.94±9.25)%were significantly higher than those before treatment(68.46±13.78)%,(32.53±9.75)%,(0.79±0.39),(16.77±7.80)%,CD3^+CD8^+and CD4^+CD25^+after treatment(37.40±5.85)%,(4.56±2.03)%were significantly lower than those before treatment(44.89±11.58)%,(5.65±1.43)%(P<0.05).In T cell subsets of cervical cancer patients,CD3^+,CD3^+CD4^+,CD4^+/CD8^+ and NK cells after treatment(53.69±11.37)%,(28.77±5.69)%,(1.02±0.39),(21.75±6.89)%were significantly higher than those before treatment(42.63±8.20)%,(25.03±5.85)%,(0.70±0.36),(17.62±7.72)%,CD3^+CD8^+ and CD4^+CD25^+ after treatment(30.00±8.42)%,(7.45±3.48)% were significantly lower than those before treatment(40.42±11.27)%,(10.44±3.70)%(P<0.05).In cytokines of ovarian cancer patients,IFN-γ after treatment(8.43±1.38)pg/mL was significantly higher than that before treatment(6.84±1.48)pg/mL,IL-10,IL-4 and IL-2 after treatment(3.50±0.76)pg/mL,(3.24±0.13)pg/mL,(3.94±1.28)pg/mL were significantly lower than those before treatment(5.23±1.30)pg/mL,(4.65±1.35)pg/mL,(6.63±2.96)pg/mL(P<0.05).TNF-α and IL-6 showed no significant difference before and after treatment(P>0.05).In cytokines of cervical patients,IFN-γand TNF-αafter treatment(38.97±30.80)pg/mL,(8.25±2.28)pg/mL were significantly higher than those before treatment(9.14±3.20)pg/mL,(4

关 键 词：细胞因子诱导的杀伤细胞 卵巢癌 宫颈癌 免疫治疗 

分 类 号：R446.63[医药卫生—诊断学]